Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context.

IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY
Multiple Sclerosis Journal Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI:10.1177/13524585241266180
Luca Prosperini, Serena Ruggieri, Shalom Haggiag, Carla Tortorella, Claudio Gasperini
{"title":"Disability patterns in multiple sclerosis: A meta-analysis on RAW and PIRA in the real-world context.","authors":"Luca Prosperini, Serena Ruggieri, Shalom Haggiag, Carla Tortorella, Claudio Gasperini","doi":"10.1177/13524585241266180","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To summarize the current evidence on relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) through a quantitative synthesis of real-world studies.</p><p><strong>Methods: </strong>Scientific databases were searched to identify suitable articles. Random-effects meta-analyses, subgroup analyses and meta-regression models were ran to provide pooled estimates of RAW and PIRA events and to identify their potential moderators (PROSPERO registration: CRD42024503895).</p><p><strong>Results: </strong>Eighteen articles met the eligibility criteria, with a pooled sample size of 52,667 patients (93% relapsing-remitting, 6% clinically isolated syndrome and 1% progressive) followed for 2.4 to 12.1 years, yielding to 415,825 patient-years. Pooled event rates for RAW and PIRA were 1.6 (95 confidence interval (CI) = 1.1-2.1) and 3.1 (95% CI = 2.3-3.9) per 100 patient-years, respectively. Less RAW events were found in cohorts including patients with progressive course (β = -0.069, <i>p</i> = 0.006) and under high-efficacy disease-modifying treatments (DMTs) (β = -0.031, <i>p</i> = 0.007), while PIRA events were directly related to older age (β = 0.397, <i>p</i> = 0.027). In addition, we found significant differences in PIRA event rates according to the criteria adopted to define confirmed disability accrual (<i>p</i> < 0.05).</p><p><strong>Discussion: </strong>PIRA accounts for most events causing disability accumulation in the real-world setting, even at the earlier disease stages, whereas RAW represents a less frequent phenomenon, likely due to effective treatments. The detection and statistical analysis of PIRA outcomes pose challenges, raising the risk of erroneous inference. When interpreting our findings, caution is needed given the wide heterogeneity of included studies.</p>","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1309-1321"},"PeriodicalIF":4.8000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241266180","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To summarize the current evidence on relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) through a quantitative synthesis of real-world studies.

Methods: Scientific databases were searched to identify suitable articles. Random-effects meta-analyses, subgroup analyses and meta-regression models were ran to provide pooled estimates of RAW and PIRA events and to identify their potential moderators (PROSPERO registration: CRD42024503895).

Results: Eighteen articles met the eligibility criteria, with a pooled sample size of 52,667 patients (93% relapsing-remitting, 6% clinically isolated syndrome and 1% progressive) followed for 2.4 to 12.1 years, yielding to 415,825 patient-years. Pooled event rates for RAW and PIRA were 1.6 (95 confidence interval (CI) = 1.1-2.1) and 3.1 (95% CI = 2.3-3.9) per 100 patient-years, respectively. Less RAW events were found in cohorts including patients with progressive course (β = -0.069, p = 0.006) and under high-efficacy disease-modifying treatments (DMTs) (β = -0.031, p = 0.007), while PIRA events were directly related to older age (β = 0.397, p = 0.027). In addition, we found significant differences in PIRA event rates according to the criteria adopted to define confirmed disability accrual (p < 0.05).

Discussion: PIRA accounts for most events causing disability accumulation in the real-world setting, even at the earlier disease stages, whereas RAW represents a less frequent phenomenon, likely due to effective treatments. The detection and statistical analysis of PIRA outcomes pose challenges, raising the risk of erroneous inference. When interpreting our findings, caution is needed given the wide heterogeneity of included studies.

多发性硬化症的残疾模式:现实世界中 RAW 和 PIRA 的荟萃分析。
摘要通过对现实世界的研究进行定量综述,总结有关复发相关恶化(RAW)和独立于复发活动的进展(PIRA)的现有证据:方法: 对科学数据库进行检索,以确定合适的文章。随机效应荟萃分析、亚组分析和荟萃回归模型提供了RAW和PIRA事件的集合估计值,并确定了其潜在的调节因素(PROSPERO注册:CRD42024503895):18篇文章符合资格标准,汇总样本量为52,667名患者(93%为复发缓解型患者,6%为临床孤立综合征患者,1%为进展型患者),随访时间为2.4至12.1年,共计415,825个患者年。RAW和PIRA的汇总事件发生率分别为每100例患者年1.6例(95置信区间(CI)=1.1-2.1)和3.1例(95% CI=2.3-3.9)。在病程进展(β = -0.069,p = 0.006)和接受高效疾病修饰治疗(DMTs)(β = -0.031,p = 0.007)的患者队列中,RAW 事件较少,而 PIRA 事件与年龄直接相关(β = 0.397,p = 0.027)。此外,我们还发现,根据界定确诊残疾的标准,PIRA 事件发生率存在显著差异(p < 0.05):讨论:在现实世界中,即使在疾病的早期阶段,PIRA 也是导致残疾累积的大多数事件,而 RAW 则是一种不太常见的现象,这可能是由于有效的治疗方法所致。PIRA 结果的检测和统计分析带来了挑战,增加了错误推断的风险。鉴于纳入研究的异质性较大,在解释我们的研究结果时需要谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Multiple Sclerosis Journal
Multiple Sclerosis Journal 医学-临床神经学
CiteScore
10.90
自引率
6.90%
发文量
186
审稿时长
3-8 weeks
期刊介绍: Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信